News

The Kate Amato Foundation is continuing to honor Childhood Cancer Awareness Month this September with two major announcements.
The foundation is awarding $75,000 to fund two groundbreaking pediatric cancer research projects. In addition, it has launched Kate’s Kindness Project, which provides immediate direct support to local children hospitalized with cancer.

They’ve partnered with the Kate Amato Foundation and are providing baskets every Friday full of goodies to brighten children’s days.

The Kate Amato Foun- dation (KAF) is continu- ing to honor Childhood Cancer Awareness Month this September with two announcements. They are awarding $75,000 to fund two pediatric cancer research projects, which serves the organization’s mission. The organization has also launched Kate’s Kindness Project, which provides immediate direct support to local children hospitalized with cancer.

The Kate Amato Foundation continues to honor Childhood Cancer Awareness Month this September with two exciting announcements. The foundation has awarded $75,000 to fund two groundbreaking pediatric cancer research projects. The group has also launched Kate’s Kindness Project, which provides immediate direct support to local children hospitalized with cancer.

COLUMBUS, Ohio – The National Cancer Institute at the National Institutes of Health announced it has awarded one of its Cancer Moonshot grants to Timothy Cripe, MD, PhD, chief of the division of Hematology, Oncology & Blood and Marrow Transplant and Elaine Mardis, PhD, co-executive director of the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital.

The Food and Drug Administration on Wednesday announced what the agency calls a “historic action” — the first approval of a cell-based gene therapy in the United States.

Researchers at Karolinska Institutet and Karolinska University Hospital have discovered that an anti-inflammatory drug candidate inhibiting the prostaglandin E2 producing enzyme mPGES-1 in the tumor stroma reduces tumor growth in experimental neuroblastoma models. The findings are published in EBioMedicine and open for new treatment strategies for this aggressive childhood cancer.

Seattle Children’s has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells.

The Food and Drug Administration on Wednesday approved the first-ever gene therapy in the US.

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia.